]>
IRCT20180506039549N1 IRCT 2018-10-22 Ahvaz University of Medical Sciences Effect of Alendronate in Patents with Osteoporosis and Chronic Kidney Disease Effect of Alendronate on Bone Densitometry in Osteoporetic Chronic Kidney Disease Stage 3a-3b 2018-08-06 anticipated 82 Complete https://irct.ir/trial/33312 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization With Using Six Blocks, One Group Including Intervention and another Group is Placebo, and Patients Selected Randomly According to The Blocks, Blinding description: To reduce the risk of bias, patient and assessor and statistician were blinded to know the type of treatment assigned to each person and that which patient was in which group. 3 Chronic Kidney Disease Stage 3a-3b. Intervention 1: Intervention group: Alendronate 70mg Tablet Produced by Abidi Company Will Orally be Administered to This Group once a Week Before Meals, with a Glass of Water for 6 Months. Intervention 2: Control group: Placebo is Administered to This Group in the Form of Pills with The same dose and Duration as The Intervention Group.The Placebo will be Produced at the Faculty of Pharmacy, Jundishapur University of Medical Sciences, Ahvaz, and its Appearance, Size, Taste and Color are similar to those of the main Group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Shokouh Shayanpour
Golestan St , Ahvaz
Ahvaz Iran (Islamic Republic of) 61357-12794 +98 61 3333 7077 shayanpor.sh@ajums.ac.ir Ahvaz University of Medical Sciences scientific Shokouh Shayanpour
Golestan St , Ahvaz
Ahvaz Iran (Islamic Republic of) 61357-12794 +98 61 3333 7077 shayanpour.sh@ajums.ac.ir Ahvaz University of Medical Sciences Iran (Islamic Republic of) Osteoporotic Patients with Chronic Kidney Disease Patients over 18 years of Age 18 years no limit Both Patients with hyperparathyroidism Patients with hypoparathyroidism Patients with normal Densitometry N18.3 Chronic kidney disease, stage 3 (moderate) Treatment - Drugs Placebo Intervention group: Alendronate 70mg Tablet Produced by Abidi Company Will Orally be Administered to This Group once a Week Before Meals, with a Glass of Water for 6 Months. Control group: Placebo is Administered to This Group in the Form of Pills with The same dose and Duration as The Intervention Group.The Placebo will be Produced at the Faculty of Pharmacy, Jundishapur University of Medical Sciences, Ahvaz, and its Appearance, Size, Taste and Color are similar to those of the main Group Bone density in patients with Chronic Kidney Disease Stage 3a-3b. Timepoint: Before and 6 months after study. Method of measurement: Densitometry. Ahvaz University of Medical Sciences Approved 2018-08-04 Ethics committee of Ahvaz Jundishapur University of Medical Sciences Golestan St , Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)